Dendritic cell-based nanovaccines for cancer immunotherapy

Paulis, Leonie E. M.; Mandal, Subhra; Kreutz, Martin; Figdor, Carl G.

doi:10.1016/j.coi.2013.03.001

Cited by 122 publications

(91 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The size, shape, and surface characteristics of an antigen or adjuvant have a significant impact on its immunogenicity (Bachmann and Jennings, 2010). Particulate antigen vaccine might provide advantage over the soluble antigen vaccine by serving as antigen depot and protecting the antigen from enzyme degradation, enabling targeted delivery to specific immune organs and cell types, and stimulating antigen presentation via the desired pathways at controlled release rate (Paulis et al, 2013). For example, alum adjuvant and many nano-size crystal structures can activate inflammasome and promote IL-1β release in DCs, which may facilitate the antigen presentation function of DCs and boost immune responses (Sharp et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response

Xia

Mai

et al. 2015

Cell Reports

View full text Add to dashboard Cite

SUMMARY Micro- and nano-meter size particles have become popular candidates for cancer vaccine adjuvants. However the mechanism by which such particles enhance immune responses remains unclear. Here we report a porous silicon microparticle (PSM)-based cancer vaccine that greatly enhances cross-presentation and activates type I interferon response in dendritic cells. PSM-loaded antigen exhibited prolonged early endosome localization and enhanced cross-presentation through both proteasome- and lysosome-dependent pathways. Phagocytosis of PSM by dendritic cells induced type I interferon responses through a TRIF- and MAVS-dependent pathway. Dendritic cells primed with PSM-loaded HER2 antigen produced robust CD8 T cell-dependent anti-tumor immunity in mice bearing HER2-positive mammary gland tumors. Importantly, this vaccination activated tumor immune microenvironment with elevated levels of intra-tumor type I interferon and MHC-II expression, abundant CD11c+ dendritic cell infiltration, and tumor-specific cytotoxic T cell responses. These findings highlight the potential for PSM as an immune adjuvant to potentiate dendritic cell-based cancer immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response

Xia

Mai

et al. 2015

Cell Reports

View full text Add to dashboard Cite

show abstract

“…A summary of clinical trials using ex vivo DC vaccines is provided in a recent review [52]. Widespread application of adoptive DC transfer has been limited by cost, labor requirements and technical complexity of the procedure [13,65]. Targeting dendritic cells in situ will circumvent these problems and provide readily available off-the-shelf products.…”

Section: Ex Vivo As Opposed To In Situ Dendritic Cell Targetingmentioning

confidence: 99%

Targeting human dendritic cells in situ to improve vaccines

Sehgal

Dhodapkar

2014

Immunology Letters

View full text Add to dashboard Cite

Dendritic cells (DCs) provide a critical link between innate and adaptive immunity. The potent antigen presenting properties of DCs makes them a valuable target for the delivery of immunogenic cargo. Recent clinical studies describing in situ DC targeting with antibodymediated targeting of DC receptor through DEC-205 provide new opportunities for the clinical application of DC-targeted vaccines. Further advances with nanoparticle vectors which can encapsulate antigens and adjuvants within the same compartment and be targeted against diverse DC subsets also represent an attractive strategy for targeting DCs. This review provides a brief summary of the rationale behind targeting dendritic cells in situ, the existing pre-clinical and clinical data on these vaccines and challenges faced by the next generation DC-targeted vaccines.

show abstract

“…11 Recent strategies for developing preventative and therapeutic vaccines have focused on the ability to deliver antigen to dendritic cells (DCs) in a targeted and prolonged manner. 12 DCs are the most effective antigen-presenting cells (APCs), and have a crucial role in initiating T-cell mediated immunity. DCs can control a substantial part of the adaptive immune response by internalizing and processing antigen through MHC class I and class II pathways and, finally, presenting antigenic peptides to CD8 C and CD4 C T lymphocytes.…”

Section: Introductionmentioning

confidence: 99%

Multifunctional nanoparticles for cancer immunotherapy

Saleh

Shojaosadati

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

During the last decades significant progress has been made in the field of cancer immunotherapy. However, cancer vaccines have not been successful in clinical trials due to poor immunogenicity of antigen, limitations of safety associated with traditional systemic delivery as well as the complex regulation of the immune system in tumor microenvironment. In recent years, nanotechnology-based delivery systems have attracted great interest in the field of immunotherapy since they provide new opportunities to fight the cancer. In particular, for delivery of cancer vaccines, multifunctional nanoparticles present many advantages such as targeted delivery to immune cells, co-delivery of therapeutic agents, reduced adverse outcomes, blocked immune checkpoint molecules, and amplify immune activation via the use of stimuli-responsive or immunostimulatory materials. In this review article, we highlight recent progress and future promise of multifunctional nanoparticles that have been applied to enhance the efficiency of cancer vaccines.

show abstract

Dendritic cell-based nanovaccines for cancer immunotherapy

Cited by 122 publications

References 69 publications

Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response

Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response

Targeting human dendritic cells in situ to improve vaccines

Multifunctional nanoparticles for cancer immunotherapy

Contact Info

Product

Resources

About